- Home
- HUSA vs MREO Comparison
HUSA vs MREO Comparison
Compare HUSA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUSA
- MREO
- Stock Information
- Founded
- HUSA N/A
- MREO 2015
- Country
- HUSA United States
- MREO United Kingdom
- Employees
- HUSA N/A
- MREO N/A
- Industry
- HUSA Oil & Gas Production
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- HUSA Energy
- MREO Health Care
- Exchange
- HUSA Nasdaq
- MREO Nasdaq
- Market Cap
- HUSA 339.8M
- MREO 326.1M
- IPO Year
- HUSA N/A
- MREO N/A
- Fundamental
- Price
- HUSA N/A
- MREO $1.97
- Analyst Decision
- HUSA
- MREO Strong Buy
- Analyst Count
- HUSA 0
- MREO 5
- Target Price
- HUSA N/A
- MREO $7.40
- AVG Volume (30 Days)
- HUSA 197.8K
- MREO 1.3M
- Earning Date
- HUSA 11-13-2025
- MREO 11-11-2025
- Dividend Yield
- HUSA N/A
- MREO N/A
- EPS Growth
- HUSA N/A
- MREO N/A
- EPS
- HUSA N/A
- MREO N/A
- Revenue
- HUSA N/A
- MREO $500,000.00
- Revenue This Year
- HUSA N/A
- MREO N/A
- Revenue Next Year
- HUSA N/A
- MREO $72.16
- P/E Ratio
- HUSA N/A
- MREO N/A
- Revenue Growth
- HUSA N/A
- MREO N/A
- 52 Week Low
- HUSA $3.85
- MREO $1.47
- 52 Week High
- HUSA $32.00
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- HUSA 33.73
- MREO 56.96
- Support Level
- HUSA $6.10
- MREO $1.92
- Resistance Level
- HUSA $6.77
- MREO $2.12
- Average True Range (ATR)
- HUSA 0.39
- MREO 0.11
- MACD
- HUSA 0.07
- MREO 0.01
- Stochastic Oscillator
- HUSA 7.11
- MREO 60.41
About HUSA Houston American Energy Corporation
Houston American Energy Corp is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. Its properties, and operations, are in the U.S. Permian Basin, the U.S. Gulf Coast region, particularly Louisiana, and the South American country of Colombia. Geographically, the company currently has operations in two geographical areas, the United States, from where it derives maximum revenue, and Colombia.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).